Related references
Note: Only part of the references are listed.Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia
Richard T. Maziarz et al.
BONE MARROW TRANSPLANTATION (2021)
Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Catherine J. Lee et al.
BONE MARROW TRANSPLANTATION (2019)
CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
Marcos de Lima et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Relapse and Survival After Transplantation for Complex Karyotype Acute Myeloid Leukemia: A Report From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and The University of Texas MD Anderson Cancer Center
Stefan O. Ciurea et al.
CANCER (2018)
Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial
Andreas Burchert et al.
BLOOD (2018)
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia
Daniel J. DeAngelo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation
Maria R. Khouri et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials
Armin Rashidi et al.
BLOOD (2016)
Azacitidine As Post-Allograft Maintenance Helps Reduce Relapse Risk in High-Risk MDS and AML
Jean El Cheikh et al.
BLOOD (2016)
Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study
Nelli Bejanyan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
Madan H. Jagasia et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia
Andrew Wei et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
CME Information: Acute myeloid leukemia: 2014 update on risk-stratification and management
Elihu H. Estey
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Lenalidomide-based maintenance therapy reduces TNF Receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients
Chindu Govindaraj et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation
Melissa Alsina et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study
Christine Wolschke et al.
EXPERIMENTAL HEMATOLOGY (2013)
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation
Christoph Schmid et al.
BLOOD (2012)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial
Katja Sockel et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Targeted immunotherapy for acute myeloid leukemia
Sumithira Vasu et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2011)
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial
Evelien Kneppers et al.
BLOOD (2011)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells
M. Lioznov et al.
BONE MARROW TRANSPLANTATION (2010)
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation.
Ted A. Gooley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications
David H. Chang et al.
BLOOD (2006)
Share Paper
